Get the Stockscreener App
1.21
2.42%
-0.03
After Hours:
1.21
NanoViricides Inc stock is traded at $1.21, with a volume of 180.66K.
It is down -2.42% in the last 24 hours and down -15.38% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.24
Open:
$1.22
24h Volume:
180.66K
Relative Volume:
0.52
Market Cap:
$26.10M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.7286
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
+7.08%
1M Performance:
-15.38%
6M Performance:
-12.95%
1Y Performance:
-12.95%
1-Day Range:
$1.18
$1.23
1-Week Range:
$1.14
$1.31
52-Week Range:
$0.94
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.21 | 26.74M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
How risky is NanoViricides Inc. stock nowJuly 2025 Snapshot & Advanced Swing Trade Entry Alerts - ulpravda.ru
Is NanoViricides Inc. stock oversold or undervaluedQuarterly Trade Report & Low Drawdown Trading Strategies - ulpravda.ru
How analysts rate NanoViricides Inc. stock todayQuarterly Profit Report & Weekly Stock Breakout Alerts - ulpravda.ru
Can NanoViricides Inc. stock weather global recessionBull Run & Daily Profit Focused Screening - ulpravda.ru
Is NanoViricides Inc stock oversold or undervaluedMarket Growth Review & Reliable Entry Point Trade Alerts - moha.gov.vn
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - lenconnect.com
Profit Recap: How risky is NanoViricides Inc stock nowJuly 2025 PreEarnings & Consistent Profit Alerts - moha.gov.vn
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - thespectrum.com
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - The Coloradoan
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - The Register-Guard
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Fall River Herald News
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - The Register-Guard
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - Victorville Daily Press
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - TheDailyJournal.com
Hogs Drift in a Quiet Session - Barchart.com
Cotton Faces Pressure into the Close - Barchart.com
Wild Yangtze: Echoes of Life from the River’s Rare Species - Barchart.com
Stocks slip on Wall Street as 2025 winds down - Barchart.com
QuantumScape Gained 100% in 2025 and Is Set to Generate Revenue for the First Time in 2025. Options Data Suggests You Should Play QS Stock Like This for 2026. - Barchart.com
MongoDB, AppLovin, and SoundHound AI Stocks Trade Down, What You Need To Know - Barchart.com
Why RXO (RXO) Stock Is Down Today - Barchart.com
Alibaba Was the Market’s Favorite Chinese AI Stock in 2025: What’s BABA’s 2026 Forecast? - Barchart.com
After Long Preparation, Sun Star Roofing Begins Serving the Pittsburgh Area with a Comprehensive Exterior Vision - Barchart.com
Cotton Holding onto Slight Gains on Monday - Barchart.com
Short Sellers Are Betting Against Lumentum Stock. Will They Be Proven Right? - Barchart.com
Hogs Fall to Weakness on Friday - Barchart.com
2 S&P 500 Stocks to Target This Week and 1 We Brush Off - Barchart.com
2 Reasons to Watch PYPL and 1 to Stay Cautious - Barchart.com
New Year, Even Better Liquidity for Brokers in 2026 - Barchart.com
Netflix Is Out of Favor—and That’s Why It’s Getting Interesting - Barchart.com
A Systematic Exploration of Technological Risks: Hu Jiaqi’s Foresight and Practice - Barchart.com
Sidus Space Announces Pricing of Offering - Barchart.com
CRWV Investigation: Kessler Topaz Meltzer & Check, LLP Encourages CoreWeave, Inc. (NASDAQ: CRWV) Investors with Significant Losses to Contact the Firm - Barchart.com
AI Bubble Fears Scaring You Off? Buy This Magnificent 7 Stock for Stability. - Barchart.com
Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 - Barchart.com
This Cannabis Stock Got Destroyed in 2025. Can Trump Make 2026 a Different Story? - Barchart.com
NanoViricides files to sell 7.14 shares of common stock for holders - MSN
1 Reason to Avoid MSCI and 1 Stock to Buy Instead - Barchart.com
3 Reasons to Avoid KD and 1 Stock to Buy Instead - Barchart.com
Why Are UiPath (PATH) Shares Soaring Today - Barchart.com
Cotton Holding onto Pre-Holiday Gains - Barchart.com
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Barchart.com
HALPER SADEH LLC ENCOURAGES DRIVEN BRANDS HOLDINGS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Barchart.com
What You Need to Know Ahead of Brown & Brown's Earnings Release - Barchart.com
What drives NanoViricides Inc stock priceFundamental Stock Analysis & Exceptional Profit Ideas - earlytimes.in
Trump Just Sent This Lesser-Known Stock Plunging. Should You Buy the Dip? - Barchart.com
Richtech Shows off Dex in January - Barchart.com
A $61 Billion Reason to Buy Amazon Stock for 2026 - Barchart.com
Cotton Showing Early Wednesday Gains - Barchart.com
US applications for jobless benefits fall to 214,000 last week, remain at historically healthy levels - Barchart.com
Here's what stores are open, and which ones are closed, on Christmas - Barchart.com
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):